Sportskeeda2d
“I’m a different level” - Marat Grigorian says Japanese rising star Kaito Ono has never fought an opponent of his caliber
Marat Grigorian knows Kaito Ono's game has merits, but he's confident his Japanese opponent has never faced an opponent of ...
Sportskeeda1d
Marat Grigorian doesn’t plan to fall victim to Kaito Ono’s signature tool at ONE 172: “Got to watch out for his calf kicks”
If there's anything Marat Grigorian has learned from Kaito Ono's past fights is that it's best not to mess with his stinging kicks downstairs.
One Championship on MSN1d
‘Gives Me The Edge’ – Kickboxing Superstar Marat Grigorian Details The Benefits Of Training In Thailand At Fairtex
Marat Grigorian expects to improve his focus and conditioning for his bout with Kaito Ono at ONE 172. The Armenian will spend ...
One Championship on MSN7d
‘Spirit Of Bushido’ – Kickboxing Superstar Masaaki Noiri Details Unique Traits That Make Japanese Fighters Different
The modern-day samurai will battle Tawanchai for the ONE Interim Featherweight Kickboxing World Title at ONE 172 ...
lowkickmma.com24d
Kickboxing Crossover – Marat Grigorian to face Kato Ono at ONE 172
ONE Championship veteran and former Glory and K-1 World champion Marat Grigorian will face off against Shoot boxing champion and for RISE kickboxing champion Kaito Ono at ONE 172, which is already ...
Yardbarker9d
Star-Studded ONE 172 Lineup Features 5 World Championship Bouts On March 23
ONE Championship has finalized its star-studded ONE 172: Takeru vs. Rodtang lineup for global pay-per-view on Sunday, March 23. In total, five amazing World Championship battles will be featured ...
MedCity News23d
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product ...
FiercePharma26d
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat adult patients with symptomatic tenosynovial giant cell tumor (TGCT), which is typically ...